Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2024 | Preliminary results from the FRIDA study: iadademstat and gilteritinib in FLT3-mutated R/R AML

Amir Fathi • 25 Jun 2024
EHA 2024
Acute Myeloid Leukemia Leukemia Gilteritinib Iadademstat
FRIDA

Amir Fathi, MD, MPH, Massachusetts General Hospital, Boston, MA, discusses the FRIDA study (NCT05546580), which is investigating iadademstat and gilteritinib in FLT3-mutated relapsed/refractory (R/R) acute myeloid leukemia (AML). Preliminary results show activity of this combination in this patient population, and efforts are ongoing to find the optimal doses. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Amir Fathi

0:51
Unmet needs in front-line therapy for patients with FLT3-mutated AML
Amir Fathi • 25 Jun 2024
1:05
Improving transplantation rates by increasing CR in AML
Amir Fathi • 25 Jun 2024
1:35
An overview of the main challenges to prolonging remission in AML
Amir Fathi • 25 Jun 2024
1:17
Venetoclax plus azacitidine vs intensive chemotherapy induction in fit patients with AML
Amir Fathi • 21 Nov 2023

Related Videos

1:13
Cytometry versus morphology in the monitoring of AML
Sanam Loghavi • 14 Jun 2024
0:51
Unmet needs in front-line therapy for patients with FLT3-mutated AML
Amir Fathi • 25 Jun 2024
2:57
The addition of blinatumomab to prephase and consolidation therapy in adult B-ALL
Anita Rijneveld • 17 Jun 2024
1:55
The ALPINE trial shows improved outcomes with zanubrutinib versus ibrutinib in R/R CLL
Jennifer Brown • 14 Jun 2024
The content of VJHemOnc is intended for healthcare professionals